Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardlytics, Inc.CDLX · Entity 7603 | Director | November 08, 2022 | November 10, 2022 |
| Evergy, Inc.EVRG · Entity 3282 | Director | April 01, 2020 | April 02, 2020 |
| Plum Acquisition Corp. IIIAPTMU · Entity 83854 | Director | July 27, 2021 | July 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardlytics, Inc.
Report date November 08, 2022 · Filed November 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 248,779 |
Reported balance
After 2022-11-08 transaction · row 1
1 source rowRow 1 · 2022-11-08 · Sale · Disposed 6 · Balance 248,779 F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 55,832 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 55,832 F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 53,112 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 53,112 F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.
F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.
F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.
Evergy, Inc.
Report date April 01, 2020 · Filed April 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 13,666 |
Reported balance
After 2020-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-01 · Grant · Acquired 455 · Balance 13,666 F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person. F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents. |
| Common StockSEC Table I · non-derivative | Direct | 788 |
Reported balance
Holding disclosure · report date 2020-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 788 |
Filing footnotes · ownership attribution and instrument terms
F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.
F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.
Plum Acquisition Corp. III
Report date July 27, 2021 · Filed July 27, 2021
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GREAT PLAINS ENERGY INC
Report date June 04, 2018 · Filed June 05, 2018
Section 16 reporting ended · disclosed 2018-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 1
1 source rowRow 1 · 2018-06-04 · Disposition to issuer · Disposed 1,318 · Balance 0 F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange. |
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-04 · Disposition to issuer · Disposed 11,970 · Balance 0 F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.
F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2021 Filed May 11, 2021 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,243 | $103.68 | $128,874.24 |
DisclosureSEC source: 0001666071-21-000086 · wf-form4_162076412766456.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,682 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on April 1, 2021. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $103.185 to $104.14, inclusive. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,800 | $102.35 | $184,230.00 |
DisclosureSEC source: 0001666071-21-000086 · wf-form4_162076412766456.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,925 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on April 1, 2021. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $101.90 to $102.83, inclusive. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,300 | $101.10 | $131,430.00 |
DisclosureSEC source: 0001666071-21-000086 · wf-form4_162076412766456.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,725 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on April 1, 2021. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $100.82 to $101.63, inclusive. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 802 | $100.33 | $80,464.66 |
DisclosureSEC source: 0001666071-21-000086 · wf-form4_162076412766456.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,025 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on April 1, 2021. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $99.81 to $100.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 175 | $137.63 | $24,085.25 |
DisclosureSEC source: 0001666071-21-000084 · wf-form4_162025331456265.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $137.32 to $138.05, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $135.87 | $27,174.00 |
DisclosureSEC source: 0001666071-21-000084 · wf-form4_162025331456265.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,287 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $135.14 | $40,542.00 |
DisclosureSEC source: 0001666071-21-000084 · wf-form4_162025331456265.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,487 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $134.78 to $135.40, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,325 | $133.57 | $176,980.25 |
DisclosureSEC source: 0001666071-21-000084 · wf-form4_162025331456265.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,787 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $133.15 to $133.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), and (5) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $131.19 | $39,357.00 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,827 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $131.14 to $131.27, inclusive. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 290 | $130.12 | $37,734.80 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,127 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.32, inclusive. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $129.08 | $38,724.00 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,417 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $128.76 to $129.37, inclusive. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $128.10 | $25,620.00 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,717 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $127.75 to $128.45, inclusive. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 310 | $127.02 | $39,376.20 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,917 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $126.63 to $127.27, inclusive. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 23:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 600 | $125.87 | $75,522.00 |
DisclosureSEC source: 0001666071-21-000074 · wf-form4_161947800314998.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,227 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $125.54 to $126.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 560 | $125.42 | $70,235.20 |
DisclosureSEC source: 0001666071-21-000072 · wf-form4_161886323030381.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 85,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $125.07 to $125.93, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 849 | $124.32 | $105,547.68 |
DisclosureSEC source: 0001666071-21-000072 · wf-form4_161886323030381.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 85,672 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $124.07 to $125.05, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 391 | $123.11 | $48,136.01 |
DisclosureSEC source: 0001666071-21-000072 · wf-form4_161886323030381.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 86,521 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $122.78 to $123.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), and (5) to this Form 4. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $121.06 | $24,212.00 |
DisclosureSEC source: 0001666071-21-000072 · wf-form4_161886323030381.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 86,912 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $118.43 | $23,686.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 7 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 87,112 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $116.85 | $35,055.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 87,312 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F9 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $116.43 to $117.41, inclusive. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $114.68 | $22,936.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 87,612 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F8 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $114.63 to $114.72, inclusive. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 165 | $113.31 | $18,696.15 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 87,812 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $113.08 to $113.37, inclusive. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 800 | $112.48 | $89,984.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 87,977 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $112.06 to $112.82, inclusive. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 335 | $111.23 | $37,262.05 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 88,777 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $111.00 to $111.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (6), (7), (8), and (9) to this Form 4. F5 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Unit · Derivative | 13,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000062 · wf-form4_161783256809265.xml · derivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,635 Underlying: Common Stock · 13,635 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date. F2 · derivative.expiration_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Unit · Derivative | 14,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · derivative · entry 8 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,759 Underlying: Common Stock · 14,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F10 · derivative.exercise_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date. F10 · derivative.expiration_date: The RSUs shall vest in equal amounts annually over four years on the anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer on such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 14,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000048 · wf-form4_161766804612602.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the underlying vested shares of common stock of the Issuer which have not been delivered. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 500 | $129.40 | $64,700.00 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $129.13 to $129.80, inclusive. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $127.86 | $25,572.00 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,408 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $127.81 to $127.91, inclusive. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 441 | $127.09 | $56,046.69 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,608 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $126.70 to $127.43, inclusive. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $125.60 | $25,120.00 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,049 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $125.58 to $125.61, inclusive. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $124.24 | $12,424.00 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,249 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:42 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 559 | $123.64 | $69,114.76 |
DisclosureSEC source: 0001666071-21-000041 · wf-form4_161670853469342.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,349 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $123.18 to $124.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $132.81 | $26,562.00 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $132.56 to $133.05, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 578 | $131.69 | $76,116.82 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $131.41 to $131.98, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $130.18 | $13,018.00 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,890 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $128.58 | $38,574.00 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 89,990 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $128.18 to $128.85, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 622 | $127.39 | $79,236.58 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,290 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $127.18 to $127.56, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $125.26 | $25,052.00 |
DisclosureSEC source: 0001666071-21-000039 · wf-form4_161601493600025.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,912 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $125.04 to $125.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $139.75 | $55,900.00 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $139.66 to $139.79, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $138.93 | $27,786.00 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91,512 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $138.55 to $139.30, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 202 | $138.16 | $27,908.32 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91,712 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $137.47 to $138.40, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $135.84 | $40,752.00 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91,914 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $135.59 to $136.17, inclusive. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 798 | $134.42 | $107,267.16 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 92,214 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $134.09 to $135.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5), (6) and (7) to this Form 4. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:56 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $132.75 | $13,275.00 |
DisclosureSEC source: 0001666071-21-000031 · wf-form4_161480852584510.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,012 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $141.62 | $28,324.00 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,908 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $141.45 to $141.79, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $139.66 | $27,932.00 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,108 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $139.49 to $139.83, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 402 | $139.21 | $55,962.42 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,308 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $138.47 to $139.44, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $137.33 | $41,199.00 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,710 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $136.70 to $137.65, inclusive. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 598 | $135.74 | $81,172.52 |
DisclosureSEC source: 0001666071-21-000013 · wf-form4_161420118568159.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,010 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $135.35 to $136.08, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.